What the FDA labels say about taking them together
Linezolid and oxycodone
Oxycodone's FDA label of May 6, 2026 names linezolid in its drug interactions section; linezolid's label does not name oxycodone itself but warns about its class (Opioids (opioid agonists)). The oxycodone label: “The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome.”
Check it at the source: the linezolid FDA label on DailyMed (effective June 19, 2026, Hospira, Inc.); the oxycodone FDA label on DailyMed (effective May 6, 2026, Rhodes Pharmaceuticals LLC).
What does the linezolid label say about oxycodone?
Linezolid's label does not name oxycodone itself; it warns about its class (Opioids (opioid agonists)):
Linezolid label, warnings and precautionsSpontaneous reports of serotonin syndrome including fatal cases associated with the concomitant use of linezolid and serotonergic agents have been reported. Commonly used serotonergic agents include serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, buspirone, serotonin 5-HT1 receptor agonists (triptans), and opioids, including meperidine.
Linezolid label, warnings and precautionsSpontaneous reports of serotonin syndrome including fatal cases associated with the concomitant use of ZYVOX and serotonergic agents have been reported. Commonly used serotonergic agents include serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, buspirone, serotonin 5‑HT1 receptor agonists (triptans), and opioids, including meperidine.
Source: FDA drug label (Linezolid), Hospira, Inc., effective June 19, 2026 (SPL set c401f1a8-cc37-461b-bfef-f2e156629bf8), via openFDA; the full label on DailyMed
What does the oxycodone label say about linezolid?
Oxycodone label, drug interactionsSerotonergic Drugs Clinical Impact: The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome. … monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).
Roxicodone label (SpecGx LLC, April 24, 2026), drug interactionsSerotonergic Drugs Clinical Impact: The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome. … monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).
Source: FDA drug label (Roxicodone, NDA021011), SpecGx LLC, effective April 24, 2026 (SPL set 5a8157d3-ba20-4abf-b0d4-6ad141b31d63), via openFDA
Source: FDA drug label (Oxaydo, NDA202080), Zyla Life Sciences US LLC, effective January 4, 2026 (SPL set cff0c64a-63f5-4b3c-909a-cdecf6755cbe), via openFDA
Source: FDA drug label (Oxycodone Hydrochloride), Rhodes Pharmaceuticals LLC, effective May 6, 2026 (SPL set a5162476-1217-41c0-bc7e-0a0f123f069f), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Linezolid | Oxycodone | |
|---|---|---|
| Labeled for | Bacterial infections | Pain |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $1.44 per tablet 600 mg tablet | $0.0884 per tablet 5 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once